Market Overview

UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking For Better Entry

Related ALKS
US Stock Futures Rise Ahead Of Economic Data
Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc

Credit Suisse initiated coverage on Alkermes (NASDAQ: ALKS) with a Neutral rating and a $24.00 price target.

Credit Suisse said, "ALKS has an attractive long-term story, but we initiate at Neutral given the potential for a better entry point. Considering ALKS is up 21% YTD (Biotech up 7%, Pharma 4%), some 1H 2013 profit-taking and a potentially negative ALKS 5461 readout pose near-term risks. Conversely, a period of outperformance could start in 2H13 with our anticipated phase 3 success of aripiprazole lauroxil, a.k.a 9070 (2020 sales at $450MM; 70% probability of success). The 2014 dual chamber pen launch for Bydureon is also likely to be a positive inflection point for that franchise with positive readthrough to ALKS. At $20 the stock is more compelling given our near and long term views."

Alkermes closed at $22.19 on Wednesday.

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters